Natixis’s Bio-Techne TECH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-11,286
Closed -$590K 1359
2026
Q1
$590K Buy
+11,286
New +$677K ﹤0.01% 782
2025
Q4
Sell
-86,534
Closed -$4.81M 1298
2025
Q3
$4.81M Buy
86,534
+61,543
+246% +$3.3M 0.02% 437
2025
Q2
$1.29M Buy
24,991
+11,306
+83% +$568K 0.01% 571
2025
Q1
$798K Buy
13,685
+3,273
+31% +$222K ﹤0.01% 601
2024
Q4
$750K Buy
+10,412
New +$765K ﹤0.01% 651
2024
Q3
Sell
-14,789
Closed -$1.06M 1104
2024
Q2
$1.06M Buy
+14,789
New +$1.09M 0.01% 501
2024
Q1
Sell
-16,823
Closed -$1.3M 1227
2023
Q4
$1.3M Buy
+16,823
New +$1.11M 0.01% 478
2023
Q1
Sell
-1,150
Closed -$95.3K 1187
2022
Q4
$95.3K Sell
1,150
-13,830
-92% -$1.1M ﹤0.01% 874
2022
Q3
$1.07M Buy
14,980
+2,884
+24% +$249K 0.01% 754
2022
Q2
$1.05M Buy
+12,096
New +$1.13M ﹤0.01% 815
2021
Q4
Sell
-4,348
Closed -$527K 1351
2021
Q3
$527K Buy
4,348
+1,172
+37% +$143K ﹤0.01% 1005
2021
Q2
$358K Sell
3,176
-19,224
-86% -$2.02M ﹤0.01% 766
2021
Q1
$2.14M Buy
+22,400
New +$2.04M 0.01% 681
2019
Q3
Sell
-81,620
Closed -$4.25M 916
2019
Q2
$4.25M Buy
81,620
+27,380
+50% +$1.38M 0.03% 353
2019
Q1
$2.67M Buy
+54,240
New +$2.44M 0.02% 465
2017
Q2
Sell
-9,712
Closed -$247K 978
2017
Q1
$247K Buy
+9,712
New +$251K ﹤0.01% 802

Other funds holding TECH

Natixis's TECH Position: Q2 2026 in Review

Natixis sold out of Bio-Techne (TECH) in Q2 2026, closing a stake of 11,286 shares — an estimated $590K sold.

Natixis first reported a position in TECH in Q1 2017 and held it in 16 quarters. The position peaked at $4.81M in Q3 2025. 596 funds tracked by Wall St. Rank hold TECH as of Q2 2026.

  • Natixis reported no remaining Bio-Techne position as of Q2 2026 after selling out during the quarter.
  • Natixis sold 11,286 Bio-Techne shares in Q2 2026, an estimated $590K.
  • Natixis first reported a position in Bio-Techne in Q1 2017 and held it in 16 quarters.
  • Natixis's Bio-Techne position peaked at $4.81M in Q3 2025.
  • 596 funds tracked by Wall St. Rank held Bio-Techne as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.